vs
奎斯特诊断（IMDX）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是奎斯特诊断的197.3倍（$224.7M vs $1.1M）。NEOGEN CORP净利率更高（-7.1% vs -2015.4%，领先2008.3%）。NEOGEN CORP同比增速更快（-2.8% vs -23.4%）。NEOGEN CORP自由现金流更多（$7.8M vs $-7.0M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs -0.9%）
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
IMDX vs NEOG — 直观对比
营收规模更大
NEOG
是对方的197.3倍
$1.1M
营收增速更快
NEOG
高出20.5%
-23.4%
净利率更高
NEOG
高出2008.3%
-2015.4%
自由现金流更多
NEOG
多$14.8M
$-7.0M
两年增速更快
IMDX
近两年复合增速
-0.9%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $224.7M |
| 净利润 | $-23.0M | $-15.9M |
| 毛利率 | 42.5% | 47.5% |
| 营业利润率 | -2057.5% | -2.4% |
| 净利率 | -2015.4% | -7.1% |
| 营收同比 | -23.4% | -2.8% |
| 净利润同比 | 31.5% | 96.5% |
| 每股收益（稀释后） | $-0.75 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMDXNEOG
| Q4 25 | $1.1M | $224.7M | ||
| Q3 25 | $260.0K | $209.2M | ||
| Q2 25 | $518.0K | $225.4M | ||
| Q1 25 | $2.1M | $221.0M | ||
| Q4 24 | $1.5M | $231.3M | ||
| Q3 24 | $115.0K | $217.0M | ||
| Q2 24 | $104.0K | $236.8M | ||
| Q1 24 | $176.0K | $228.8M |
净利润IMDXNEOG
| Q4 25 | $-23.0M | $-15.9M | ||
| Q3 25 | $-10.9M | $36.3M | ||
| Q2 25 | $-9.7M | $-612.3M | ||
| Q1 25 | $-6.7M | $-10.9M | ||
| Q4 24 | $-33.5M | $-456.3M | ||
| Q3 24 | $-13.5M | $-12.6M | ||
| Q2 24 | $-4.5M | $-5.4M | ||
| Q1 24 | $-9.1M | $-2.0M |
毛利率IMDXNEOG
| Q4 25 | 42.5% | 47.5% | ||
| Q3 25 | 53.5% | 45.4% | ||
| Q2 25 | 67.6% | 41.2% | ||
| Q1 25 | 62.0% | 49.9% | ||
| Q4 24 | 40.0% | 49.0% | ||
| Q3 24 | 43.5% | 48.4% | ||
| Q2 24 | 48.1% | 47.9% | ||
| Q1 24 | 25.6% | 51.1% |
营业利润率IMDXNEOG
| Q4 25 | -2057.5% | -2.4% | ||
| Q3 25 | -4249.2% | -7.7% | ||
| Q2 25 | -1900.0% | -271.1% | ||
| Q1 25 | -318.0% | 2.4% | ||
| Q4 24 | -2262.9% | -197.8% | ||
| Q3 24 | -11752.2% | 1.0% | ||
| Q2 24 | -4453.8% | 5.5% | ||
| Q1 24 | -5265.3% | 5.3% |
净利率IMDXNEOG
| Q4 25 | -2015.4% | -7.1% | ||
| Q3 25 | -4174.6% | 17.4% | ||
| Q2 25 | -1880.7% | -271.6% | ||
| Q1 25 | -312.0% | -4.9% | ||
| Q4 24 | -2255.1% | -197.3% | ||
| Q3 24 | -11733.0% | -5.8% | ||
| Q2 24 | -4355.8% | -2.3% | ||
| Q1 24 | -5186.9% | -0.9% |
每股收益（稀释后）IMDXNEOG
| Q4 25 | $-0.75 | $-0.07 | ||
| Q3 25 | $-0.34 | $0.17 | ||
| Q2 25 | $-0.30 | $-2.82 | ||
| Q1 25 | $-0.26 | $-0.05 | ||
| Q4 24 | $-2.19 | $-2.10 | ||
| Q3 24 | $-0.98 | $-0.06 | ||
| Q2 24 | $-0.36 | $-0.02 | ||
| Q1 24 | $-1.13 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $145.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-31.5M | $2.1B |
| 总资产 | $25.8M | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMDXNEOG
| Q4 25 | $11.6M | $145.3M | ||
| Q3 25 | $18.7M | $138.9M | ||
| Q2 25 | $24.3M | $129.0M | ||
| Q1 25 | $31.0M | $127.7M | ||
| Q4 24 | $8.6M | $140.2M | ||
| Q3 24 | $3.4M | $120.5M | ||
| Q2 24 | $9.3M | $170.9M | ||
| Q1 24 | $5.6M | $168.4M |
股东权益IMDXNEOG
| Q4 25 | $-31.5M | $2.1B | ||
| Q3 25 | $-9.2M | $2.1B | ||
| Q2 25 | $1.1M | $2.1B | ||
| Q1 25 | $10.2M | $2.7B | ||
| Q4 24 | $-12.3M | $2.7B | ||
| Q3 24 | $9.7M | $3.1B | ||
| Q2 24 | $22.7M | $3.1B | ||
| Q1 24 | $11.6M | $3.1B |
总资产IMDXNEOG
| Q4 25 | $25.8M | $3.4B | ||
| Q3 25 | $43.9M | $3.4B | ||
| Q2 25 | $50.5M | $3.4B | ||
| Q1 25 | $60.4M | $4.0B | ||
| Q4 24 | $35.1M | $4.1B | ||
| Q3 24 | $70.2M | $4.5B | ||
| Q2 24 | $74.7M | $4.5B | ||
| Q1 24 | $71.0M | $4.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-7.0M | $7.8M |
| 自由现金流率自由现金流/营收 | -616.7% | 3.5% |
| 资本支出强度资本支出/营收 | 129.9% | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-25.4M | $-18.5M |
8季度趋势，按日历期对齐
经营现金流IMDXNEOG
| Q4 25 | $-5.5M | $19.4M | ||
| Q3 25 | $-4.5M | $10.9M | ||
| Q2 25 | $-6.3M | $16.4M | ||
| Q1 25 | $-5.9M | $19.5M | ||
| Q4 24 | $-5.4M | $40.3M | ||
| Q3 24 | $-5.5M | $-17.9M | ||
| Q2 24 | $-6.0M | $26.7M | ||
| Q1 24 | $-3.8M | $-30.2M |
自由现金流IMDXNEOG
| Q4 25 | $-7.0M | $7.8M | ||
| Q3 25 | $-5.6M | $-13.1M | ||
| Q2 25 | $-6.6M | $349.0K | ||
| Q1 25 | $-6.2M | $-13.4M | ||
| Q4 24 | $-5.6M | $23.1M | ||
| Q3 24 | $-5.6M | $-56.3M | ||
| Q2 24 | $-6.2M | $2.5M | ||
| Q1 24 | $-3.9M | $-62.3M |
自由现金流率IMDXNEOG
| Q4 25 | -616.7% | 3.5% | ||
| Q3 25 | -2135.4% | -6.3% | ||
| Q2 25 | -1279.5% | 0.2% | ||
| Q1 25 | -288.4% | -6.1% | ||
| Q4 24 | -374.5% | 10.0% | ||
| Q3 24 | -4884.3% | -26.0% | ||
| Q2 24 | -5931.7% | 1.1% | ||
| Q1 24 | -2189.8% | -27.2% |
资本支出强度IMDXNEOG
| Q4 25 | 129.9% | 5.2% | ||
| Q3 25 | 403.8% | 11.5% | ||
| Q2 25 | 67.4% | 7.1% | ||
| Q1 25 | 14.4% | 14.9% | ||
| Q4 24 | 14.4% | 7.4% | ||
| Q3 24 | 75.7% | 17.7% | ||
| Q2 24 | 183.7% | 10.2% | ||
| Q1 24 | 13.6% | 14.0% |
现金转化率IMDXNEOG
| Q4 25 | — | — | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMDX
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
